Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML).
Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for …

Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer
therapies. Antibody-based agents targeting the cancer biomarkers include monoclonal …

Background Previous trials demonstrated evidence involving the total effects of gemtuzumab
ozogamicin (GO), an anti-CD33 humanized antibody, on treating acute myeloid leukemia …

Cancer is a leading cause of millions of deaths worldwide and, despite the improvements in
molecular biology, issues concerning how to advance cancer treatment are still relevant …

Background In a star-shaped network, pairwise comparisons link treatments with a reference
treatment (often placebo or standard care), but not with each other. Thus, comparisons …